Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financi...( BERKELEY Calif. Nov. 1 /- Dynavax...),Health

BERKELEY, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2007. The results do not include the financial impact of today's arrangement with Merck.

As of September 30, 2007, Dynavax reported cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI) totaling $68.7 million. This compares to $86.2 million at December 31, 2006.

"During the quarter, we made significant clinical progress and increased financial resources for our allergy and flu programs," said Dino Dina, MD, president and chief executive officer. "These events plus issuance of a landmark patent reflected a quarter of focused and productive work at Dynavax. However, today's announcement of a global partnership with Merck & Co. represents our most important accomplishment this year. With Merck as our commercialization partner, we could be the first company to bring a TLR9-based product to the market. The Merck deal increases the potential to capture the market opportunity and significantly improves our financial outlook for 2008 and beyond."

Total revenues were $1.0 million and $4.8 million for the three and nine months ended September 30, 2007, respectively, compared to $1.6 million and $2.4 million for the same periods in 2006. The increase in revenues for the nine month period resulted from our collaboration with AstraZeneca and grant revenue primarily from the NIH. The reported revenues do not include collaboration funding from SDI. Including the collaboration funding from SDI, pro forma revenues were $2.9 million and $13.3 million, respectively, for the three and nine
'/>"/>